Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07802704 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Name: A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) — clinical trial record (NCT07802704)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2026-09-22

View on ClinicalTrials.gov ↗

This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.

Trial Details

NCT Number	NCT07802704
Lead Sponsor	GlaxoSmithKline
Conditions	Neoplasms, Prostate
Enrollment	684 participants
Start Date	2026-09-22
Primary Completion	2029-12-19 (estimated)
Study Completion	2029-12-19 (estimated)
Updated on ClinicalTrials.gov	2026-09-03